143 related articles for article (PubMed ID: 16280407)
1. Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes.
Higgins TL; Steingrub JS; Tereso GJ; Tidswell MA; McGee WT
J Intensive Care Med; 2005; 20(6):339-45. PubMed ID: 16280407
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
[TBL] [Abstract][Full Text] [Related]
3. Drotrecogin alfa (recombinant human activated protein C) in severe sepsis--a New Zealand viewpoint.
Liang J; Streat S; Torrance J; Sleigh J; Freebairn R; Ramsay M
N Z Med J; 2003 Sep; 116(1181):U586. PubMed ID: 14581969
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
[TBL] [Abstract][Full Text] [Related]
6. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
[TBL] [Abstract][Full Text] [Related]
7. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
Micek ST; Isakow W; Shannon W; Kollef MH
Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
[TBL] [Abstract][Full Text] [Related]
9. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.
Sollet JP; Garber GE
Am J Surg; 2002 Dec; 184(6A Suppl):S11-8. PubMed ID: 12521613
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
Sacristán JA; Prieto L; Huete T; Artigas A; Badia X; Chinn C; Hudson P
Gac Sanit; 2004; 18(1):50-7. PubMed ID: 14980173
[TBL] [Abstract][Full Text] [Related]
11. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
McLeay AM
Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
[TBL] [Abstract][Full Text] [Related]
12. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.
Barie PS; Williams MD; McCollam JS; Bates BM; Qualy RL; Lowry SF; Fry DE;
Am J Surg; 2004 Sep; 188(3):212-20. PubMed ID: 15450822
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.
Neilson AR; Burchardi H; Chinn C; Clouth J; Schneider H; Angus D
J Crit Care; 2003 Dec; 18(4):217-27. PubMed ID: 14691895
[TBL] [Abstract][Full Text] [Related]
14. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
Frampton JE; Foster RH
Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
[TBL] [Abstract][Full Text] [Related]
15. Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated).
Levy H; Laterre PF; Bates B; Qualy RL
Crit Care; 2005 Oct; 9(5):R502-7. PubMed ID: 16277711
[TBL] [Abstract][Full Text] [Related]
16. Drotrecogin Alfa (Activated): From Bench to Practical Use at the Bedside. Proceedings of meetings of the Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Clinical Evaluation Committee.
Am J Surg; 2002 Dec; 184(6A Suppl):1S-49S. PubMed ID: 12521610
[No Abstract] [Full Text] [Related]
17. Drotrecogin alfa (activated) in severe falciparum malaria.
Kendrick BJ; Gray AG; Pickworth A; Watters MP
Anaesthesia; 2006 Sep; 61(9):899-902. PubMed ID: 16922759
[TBL] [Abstract][Full Text] [Related]
18. Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).
Morris PE; Light RB; Garber GE
Am J Surg; 2002 Dec; 184(6A Suppl):S19-24. PubMed ID: 12521614
[TBL] [Abstract][Full Text] [Related]
19. Drotrecogin alfa (activated) for severe sepsis.
Maglio D
Conn Med; 2002 Mar; 66(3):145-50. PubMed ID: 11957766
[No Abstract] [Full Text] [Related]
20. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
